Celgene Corp (NASDAQ:CELG)

CAPS Rating: 5 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

1
Player Avatar Jeffreyw (93.84) Submitted: 10/25/2010 4:13:10 PM : Outperform Start Price: $28.85 CELG Score: +152.37

Big investment in discovery and production of new therapies. Monitizing these treatments will take time, but could be huge.

Featured Broker Partners


Advertisement